Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Tobacco companies deliberately kept findings of cancer-causing radioactive particles from the public

Tobacco companies deliberately kept findings of cancer-causing radioactive particles from the public

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

Engineered virus shows promise in cancer therapy via bloodstream

Engineered virus shows promise in cancer therapy via bloodstream

Patients with liver disease may now access UCSD's new Nevada clinic

Patients with liver disease may now access UCSD's new Nevada clinic

Scientists aim to tackle Hawaii's liver cancer problem with improved detection

Scientists aim to tackle Hawaii's liver cancer problem with improved detection

Survival for patients with HCC increases with radioembolization

Survival for patients with HCC increases with radioembolization

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Should we be screening blood for hepatisi G?

Should we be screening blood for hepatisi G?

Saffron promotes apoptosis and inhibits growth of cancerous cells

Saffron promotes apoptosis and inhibits growth of cancerous cells

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Novel therapy shrinks tumors without collateral damage

Novel therapy shrinks tumors without collateral damage

Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma

Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.